Teufel A, Gerken M, Fürst A, et al. - As there are controversies concerning administration of adjuvant chemotherapy in high-risk Union for International Cancer Control (UICC) stage II disease (eg, T4 tumors), researchers conducted this population-based multicenter cohort study to determine the influence of adjuvant chemotherapy on survival and recurrence rates in high-risk UICC stage II T4N0M0 tumors. Based on an anonymised nationwide ADT data set from 31 clinical cancer registries, a total of 6,651 patients with a T4 tumor of the colon were identified, of whom 6,131 were identified as eligible for survival analysis. With a subset of 3,986 patients, a matched-pair analysis based on propensity scores (PSM) was conducted. Findings suggest adjuvant chemotherapy as significantly beneficial for patients with T4 UICC stage II colon cancer in terms of overall survival, recurrence rate, and relapse-free survival. Based on these findings, they emphasize providing adjuvant chemotherapy to these patients.